Case Report

Levitronix bilateral ventricular assist device, a bridge to recovery in a patient with acute fulminant myocarditis and concomitant cerebellar infarction

Yi-Fan Huang, Po-Shun Hsu, Chien-Sung Tsai, Yi-Ting Tsai, Chih-Yuan Lin, Hong-Yan Ke, Yi-Chang Lin, Hsiang-Yu Yang

Abstract

We report on the case of a 27-year-old male who presented to our emergency room with chest tightness, dyspnoea and cold sweats. The 12-lead electrocardiogram showed diffuse ventricular tachycardia with wide QRS complexes. Troponin-I level was elevated to 100 ng/ml. The coronary angiogram showed good patency of all three coronary vessels, and acute fulminant myocarditis was suspected. The patient underwent cardiopulmonary resuscitation in the catheter room and high-dose inotropic support was initiated to stabilise his haemodynamic status. After resuscitation, the patient was in a coma and acute stroke was highly suspected. In addition, deteriorating cardiogenic shock with acute renal failure and pulmonary oedema were also detected. Due to haemodynamic compromise despite high-dose inotropic support, a Levitronix® bilateral ventricular assist device (Bi-V AD) was implanted on an emergency basis for circulatory support. Postoperative brain computed tomography revealed acute left cerebellar infarction. Because the patient had left cerebellar infarction with right hemiplegia, heart transplantation was contraindicated. Eventually, cardiac systolic function recovered well and the patient underwent successful Bi-V AD removal after a total of 18 days on Levitronix® haemodynamic support. He was weaned from the ventilator two weeks later and was discharged 10 days later.

Keywords: ventricular assist device, acute myocarditis, cerebellar infarction

Submitted 1/1/17, accepted 22/1/18
Published online 7/2/18
Cardiovasc J Afr 2018; 29: e1–e4 www.cvja.co.za
DOI: 10.5830/CVJA-2018-009

In the past two decades, intra-aortic balloon pump and extra-corposreal membrane oxygenation (ECMO) have been predominantly used at our centre as a bridge, either to cardiac transplantation or to recovery in patients with decompensated heart failure. However, most patients die because of either ECMO-related morbidity or systemic malperfusion if cardiac function does not recover in time and cardiac transplantation is contraindicated in this period. In such patients, Levitronix® bilateral ventricular assist device (Bi-V AD) could provide temporary cardiac support for a much longer period than ECMO. Our experience with this case indicates that timely implantation of Bi-V AD can function as a bridge to recovery in patients with acute fulminant myocarditis, particularly when heart transplantation is contraindicated.

Case report

A 27-year-old man was brought to our emergency room with a history of chest tightness, dyspnoea and cold sweats that had manifested a few hours earlier. However, the symptoms did not ameliorate with rest. He denied any systemic disease, except a common cold one week earlier.

The 12-lead electrocardiogram (ECG) showed diffuse ventricular tachycardia with wide QRS complexes. Troponin-I levels were elevated to 100 ng/ml. An emergency coronary angiogram showed good patency of all three coronary vessels, and acute fulminant myocarditis was suspected.

His haemodynamic status suddenly deteriorated because of ventricular fibrillation shortly after the angiogram, and cardiopulmonary resuscitation was performed for 30 minutes. His vital signs were restored after initiation of high-dose inotropic support with multiple inotropic agents (dopamine: 15 mcg/kg/min, dobutamine: 15 mcg/kg/min, norepinephrine: 32 mcg/min and epinephrine: 1 mcg/min). Because his vital signs were unstable during the coronary angiogram, we did not
perform a routine myocardial biopsy, which was necessary for the pathological diagnosis of myocarditis.

We had no choice but to send the patient back to the intensive care unit for stabilisation of the haemodynamic status. However, his level of consciousness did not improve (Glasgow coma scale score 3). Emergency brain computed tomography (CT) showed no intracranial haemorrhage, and magnetic resonance imaging (MRI) was contraindicated because infusion pumps were implanted. We were therefore unable to rule out acute stroke.

Meanwhile, 24-hour hypothermia therapy (HT) at approximately 34°C was employed for neurological protection in post-resuscitation circulatory shock. Transthoracic echocardiogram showed general hypokinesia of both ventricles (left ventricular ejection fraction 15–20%). Despite these interventions, acute pulmonary oedema and deteriorating liver and renal function with progressive oliguria ensued.

To avoid multiple organ dysfunction syndrome, a continuous-flow Levitronix® CentriMag Bi-VAD (Levitronix®, Waltham, MA) was implanted via a median sternotomy under the guidance of transoesophageal echocardiography. First, the left heart vent tube was inserted from the right superior pulmonary vein into the left ventricular apex, and the arterial cannula was inserted into the ascending aorta. Second, the right heart vent tube was inserted into the right atrium, and the arterial cannula was inserted into the pulmonary artery (Fig. 1). Then purse-string sutures with non-absorbable retention sutures secured with tourniquets and spigots were tied around all the cannulae. The vital signs immediately stabilised with Bi-VAD support and the high-dose inotropic support was tapered off the next day (dopamine: 5 mcg/kg/min, dobutamine: 5 mcg/kg/min and norepinephrine: 3.7 mcg/min).

Because a Bi-VAD was inserted, systemic heparinisation therapy was administered through a peripheral line to maintain an activated clotting time (ACT) at 160–180 s using the Hemochron® Response ACT point-of-care testing system. Unfortunately, CT the following day showed an acute left cerebellar infarction (Fig. 2), which resulted in right hemiplegia. We assumed that the cerebellar infarction was caused by the cardiopulmonary resuscitation rather than VAD-related thrombus formation. To prevent post-infarct haemorrhage, we tapered the ACT to 140–160 s.

Three days later, the patient fully recovered from the coma, and his muscle power also improved. Daily echocardiography examinations showed progressive improvement of the cardiac systolic function.

When the left ventricular ejection fraction was approximately 50%, the Bi-VAD was weaned (right-VAD: 0.5 l/min; left-VAD: 0.8 l/min). The patient underwent successful Bi-VAD removal.
after a total of 18 days on Levitronix® haemodynamic support. One week later, a tracheostomy was performed, and the patient was weaned from the ventilator a week later. The follow-up CT showed chronic encephalomalacia of the left cerebellum (Fig. 3).

The patient was discharged home 10 days later, after a total hospital stay of 42 days. During out-patient follow up, no signs of heart failure or device-related complications were noted.

Discussion

Before the use of VADs became popular, ECMO played an important role in the haemodynamic support for decompensation in cases of acute heart failure at our centre. VADs provide substantially longer durability and considerably fewer complications than ECMO. According to the 2016 guidelines recommended by the International Society for Heart and Lung Transplantation, clinically severe symptomatic cerebrovascular disease may be considered a contraindication to transplantation. Our policy was to use VADs as a bridge, either to recovery or transplantation if the patient was able to recover from left cerebellar infarction with right hemiplegia.

After starting VAD, high-dose inotropic support could be tapered immediately (Table 1) to prevent vasoconstriction in the vital visceral organs. During the period with VAD support, both troponin-I levels and liver function progressively returned to normal ranges. In time, cardiac function improved and the VAD was successfully removed. Although renal function did not recover promptly and haemodialysis was necessary during the VAD period, the renal function did recover completely, albeit two weeks later after VAD removal. This means that timely VAD support could provide immediate circulatory support, enabling cessation of high-dose inotropic administration, which would cause vasoconstriction in the visceral organs, sequential ischaemia of the visceral organs, and consequent multiple organ failure.

Currently, VADs can be categorised into two major types: pulsatile-flow and continuous-flow VADs. We chose the Levitronix® VAD for the following reasons. First, recent studies showed better outcomes with continuous-flow VADs than with pulsatile-flow ones. In addition, complications associated with continuous-flow VADs, especially bleeding and thromboembolism, are lower.

![Fig. 3. The initial hypodense lesion progressed to chronic encephalomalacia of the left cerebellum (white arrow).](image_url)

| Table 1. Clinical time course |
|-------------------------------|
| Cardiac enzyme | Before VAD | POD1 | POD2 | POD3 | POD6 | POD9 | POD12 | POD15 | POD18 |
| BNP (pg/ml) | 350 | 518 | 553 | 2219 | 1974 | 584 | 590 | 405 | 363 |
| CK (U/l) | 1743 | 2609 | 3098 | 3245 | 800 | 219 | 63 | 53 | 45 |
| CKMB (U/l) | 136.6 | 67.8 | – | – | – | – | – | – | – |
| Troponin-I (ng/ml) | 90.06 | 94.02 | 60.70 | 33.65 | 6.31 | 0.68 | 0.22 | 0.11 | 0.05 |
| Renal function | | | | | | | | | |
| BUN (mg/dl) | 33 | 33 | 41 | 49 | 108 | 52 | 70 | 114 | 121 |
| Creatinine (mg/dl) | 3.4 | 3.6 | 4.6 | 4.7 | 7.7 | 5.3 | 3.8 | 3.6 | 3.1 |
| Daily urine amount (ml) | 0 | 128 | 250 | 545 | 1540 | 1120 | 1160 | 2550 | 2240 |
| Liver function | | | | | | | | | |
| GOT (U/l) | 214 | 722 | 1191 | 795 | 133 | 94 | 47 | 52 | 40 |
| GPT (U/l) | 81 | 416 | 633 | 706 | 372 | 200 | 66 | 60 | 64 |
| Total bilirubin (mg/dl) | 4.0 | 2.7 | 3.6 | 3.2 | 2.5 | 1.4 | 1.8 | 2.5 | 2.0 |
| Inotropic agent | | | | | | | | | |
| Dopamine (mcg/kg/min) | 15.0 | 5.1 | 5.1 | 3.0 | 1.8 | 2.9 | 4.7 | 4.4 | 7.6 |
| Dobutamine (mcg/kg/min) | 15.0 | 5.1 | 5.1 | 3.0 | 1.8 | 2.9 | 4.7 | 4.4 | 7.6 |
| Epinephrine (mcg/min) | 1.0 | – | – | – | – | – | – | – | – |
| Norepinephrine (mcg/min) | 32 | 3.7 | – | – | 2.0 | 1.6 | 1.2 | – | – |
| VAD flow | | | | | | | | | |
| Right (l/min) | 2.7 | 3.5 | 3.2 | 3.0 | 3.0 | 2.8 | 1.6 | | |
| Left (l/min) | 4.5 | 5.0 | 5.0 | 5.0 | 5.0 | 4.8 | 2.6 | | |
| VAD revolutions per minute | | | | | | | | | |
| Right (l/min) | 3000 | 3000 | 2900 | 2900 | 2900 | 2900 | 2700 | 1700 | |
| Left (l/min) | 4100 | 4000 | 3700 | 3700 | 3700 | 3700 | 3500 | 2000 | |
Second, we expected recovery of the stunned myocardium after the acute myocardial infarction. Therefore, we abandoned use of the most advanced VADs, such as the HeartMate II or HeartWare, in which cannulation of the ventricular apex for drainage is necessary. We rather used the Levitronix® because we could cannulate the vent tube on the right superior pulmonary vein (Fig. 1) instead of the ventricular apex. The apical location would make surgical repair much more difficult, assuming that the viable but stunned myocardium could recover and the VAD could be withdrawn. We used a Snell-tie retention suture to securely fix both the vent and perfusion tubes. This also enabled a simple and quick closure of the cannulation wounds, which would facilitate the withdrawal procedure.

Third, although various kinds of VADs are available in Taiwan, not all are reimbursed by the National Health Insurance. In Taiwan, the Levitronix® costs approximately US$12 000, while the HeartMate II or HeartWare costs over US$170 000. Only the Levitronix® is covered by the National Health Insurance. Therefore, we opted to use Levitronix® instead of the HeartMate II or HeartWare because of economic considerations.

However, complications such as coagulopathy, thromboembolisation and mechanical failure are common with VAD use. Thromboembolisation after VAD implantation resulting in cerebrovascular events is devastating. There is no optimal treatment for stroke in patients implanted with a VAD. Supportive anticoagulation therapy rather than thrombolytic therapy, which is potentially associated with greater risk of haemorrhagic events after major surgery, is obviously essential treatment in this population. In our current protocol for heparinisation therapy, we prefer to maintain the ACT at approximately 160 s to avoid major, spontaneous bleeding disasters. If there are complications such as surgical bleeding or symptoms of coagulopathy (e.g. bloody sputum, massive gastrointestinal bleeding and large subcutaneous ecchymoses), we taper the heparin dose and maintain the ACT at approximately 140 s. If VAD-related thrombosis is suspected, we aim to prolong the ACT at 180–250 s.

In the present case, the pre-VAD CT scan showed no cerebral ischaemia, but the post-VAD CT scan showed acute left cerebellar infarction (Fig. 2). Judging by the chronology of events, the stroke event was suspected to be due to cardiopulmonary resuscitation rather than VAD-related embolisation. This is because a stroke event cannot usually be detected in the acute stage (especially within 24 hours) on CT. The only imaging examination to confirm acute-stage stroke is MRI, which was not practicable for this patient. Therefore we maintained the ACT at 140–160 s rather than > 180 s. Of course, post-infarct haemorrhage is another big concern. Eventually, we did not maintain the ACT at < 140 s because the CT scan showed no post-infarct haemorrhage.

In this case, the patient suffered from concomitant fulminant myocarditis and acute cerebellar infarction. It is useful to stabilise the infarct without ischaemic expansion or haemorrhagic transformation by maintaining the ACT at 140–160 s throughout the course. Our experience in this case indicates that short-term VAD use would be the first choice for mechanical circulatory support, not only because of much shorter surgery time but also cost-effectiveness, especially in patients with unconfirmed brain damage.

Conclusion

Levitronix® VAD provides excellent short-term cardiac mechanical support for patients with severe symptomatic cerebrovascular disease. It offers patients an option, a bridge to recovery, that is not only cost-effective but also decreases cardiac trauma during potential removal.

References

1. Magovern GJ, Simpson KA. Extracorporeal membrane oxygenation for adult cardiac support: the Allegheny experience. Ann Thorac Surg 1999; 68: 655–661.
2. Hsu PS, Chen JL, Hong GJ, Tsai YT, Lin CY, Lee CY, et al. Extracorporeal membrane oxygenation for refractory cardiogenic shock after cardiac surgery: predictors of early mortality and outcome from 51 adult patients. Eur J Cardio-Thorac Surg 2010; 37: 328–333.
3. John R, Long JW, Massey HT, Griffith BP, Sun BC, Tector AJ, et al. Outcomes of a multicenter trial of the LevitronixCentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg 2011; 141: 932–939.
4. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. N Engl J Med 1998; 339: 1522–1533.
5. Arabia FA, Tsau PH, Smith RG, Nolan PE, Paramesh V, Bose RK, et al. Pediatric bridge to heart transplantation: application of the Berlin Heart, Medos and Thoratec ventricular assist devices. J Heart Lung Transplant 2006; 25: 16–21.
6. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2015; 35: 1–23.
7. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al., HeartMate II investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241–2251.
8. Fang JC. Rise of the machines-left ventricular assist devices as permanent therapy for advanced heart failure. N Engl J Med 2009; 361: 2282–2285.
9. Russell SD, Rogers JG, Milano CA, Dyke DB, Pagani FD, Aranda JM, et al., HeartMate II Clinical Investigators. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 2009; 120: 2352–2357.
10. Popov AF, Hosseini MT, Zych B, Mohite P, Hards R, Krueger H, et al. Clinical experience with HeartWare left ventricular assist device in patients with end-stage heart failure. Ann Thorac Surg 2012; 93: 810–815.
11. Eckman PM, John R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation 2012; 125: 3038–3047.
12. Froio NL, Montgomery RM, David-Neto E, Aprahamian I. Anticoagulation in acute ischemic stroke: A systematic search. Rev Assoc Med Bras 2017; 63: 50–56.